Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery
Bioconjugate Chemistry · 2026
DOI: 10.1021/acs.bioconjchem.5c00515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Ramesh Mukkamala und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, Indiana 47907, United States. Hauptthemen laut MEDLINE: Surgery, Computer-Assisted, Fluorescent Dyes, Optical Imaging, Neoplasms. Die Arbeit nennt 55 Literaturangaben. Gefördert von: NCI NIH HHS, On Target Laboratories, National Cancer Institute.
Abstract (Originalsprache)
Fluorescence-guided surgery (FGS) has emerged as a powerful tool for enhancing a surgeon's ability to locate and resect all malignant lesions, thereby improving a patient's probability of survival. While several tumor-targeted near-infrared (NIR) fluorophores have been developed to image selected cancer types, no single tumor-targeted dye has been found to image all cancers. To remedy this deficiency, we have examined the ability of a fibroblast activation protein (FAP)-targeted NIR fluorophore to broad-spectrum solid tumors when combined with pafolacianine (OTL-38, Cytalux). Pafolacianine was selected for this imaging cocktail because it highlights all cells that express either folate receptor α (a receptor that is expressed on ∼40% of human cancers) or folate receptor β (a related receptor expressed on tumor-associated macrophages and myeloid-derived suppressor cells). An FAP-targeted conjugate of the same near-infrared fluorescent dye (S0456) was also selected because it targets myofibroblasts that infiltrate virtually all solid tumors but are essentially absent from healthy tissues. In this paper, we describe the design, synthesis, and characterization of a novel FAP ligand (FAP9) and determine its affinity (Kd ∼ 2 nM) and specificity (>2000-fold over homologous enzymes) for FAP. We then quantify its ability to image many different cancer types in murine tumor models and combine it in different ratios with pafolacianine to determine the ratio that yields the highest total tumor fluorescence and tumor-to-background ratio in seven tumor models. Because the combination of the two fluorescent conjugates invariably images tumors better than either conjugate alone, and since the two-dye combination displays no obvious toxicities, we propose that a cocktail of FAP9-S0456 plus pafolacianine warrants evaluation as a candidate for intraoperative imaging of all human tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, Indiana 47907, United States.
- Division of Thoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
ORCID-Profile: Ramesh Mukkamala, Imrul Shahriar, Philip S Low
Förderung
- NCI NIH HHS
- On Target Laboratories
- National Cancer Institute
Zitieren
APA
Mukkamala, R., Mar, B. C. W., Keltner, R. G., Noble, B. A., Mahalingam, S. M., Shahriar, I., Chakraborty, S., Singhal, S., & Low, P. S. (2026). Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00515
Vancouver
Mukkamala R, Mar BCW, Keltner RG, Noble BA, Mahalingam SM, Shahriar I, et al. Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.5c00515
BibTeX
@article{Mukkamala2026,
author = {Mukkamala, Ramesh and Mar, Brandon C Wang and Keltner, Richard Gabriel and Noble, Bennett Alexander and Mahalingam, Sakkarapalayam M and Shahriar, Imrul and Chakraborty, Shrimanti and Singhal, Sunil and Low, Philip S},
title = {Design of a Pan-Tumor Fluorescence Imaging Cocktail for Fluorescence-Guided Surgery},
journal = {Bioconjugate Chemistry},
year = {2026},
doi = {10.1021/acs.bioconjchem.5c00515}
}
EUVIMED